182 related articles for article (PubMed ID: 34490074)
1. HOXA1 Is an Antagonist of ERα in Breast Cancer.
Belpaire M; Ewbank B; Taminiau A; Bridoux L; Deneyer N; Marchese D; Lima-Mendez G; Baurain JF; Geerts D; Rezsohazy R
Front Oncol; 2021; 11():609521. PubMed ID: 34490074
[TBL] [Abstract][Full Text] [Related]
2. HOXA1 binds RBCK1/HOIL-1 and TRAF2 and modulates the TNF/NF-κB pathway in a transcription-independent manner.
Taminiau A; Draime A; Tys J; Lambert B; Vandeputte J; Nguyen N; Renard P; Geerts D; Rezsöhazy R
Nucleic Acids Res; 2016 Sep; 44(15):7331-49. PubMed ID: 27382069
[TBL] [Abstract][Full Text] [Related]
3. The Pbx interaction motif of Hoxa1 is essential for its oncogenic activity.
Delval S; Taminiau A; Lamy J; Lallemand C; Gilles C; Noël A; Rezsohazy R
PLoS One; 2011; 6(9):e25247. PubMed ID: 21957483
[TBL] [Abstract][Full Text] [Related]
4. HOXA1 and TALE proteins display cross-regulatory interactions and form a combinatorial binding code on HOXA1 targets.
De Kumar B; Parker HJ; Paulson A; Parrish ME; Pushel I; Singh NP; Zhang Y; Slaughter BD; Unruh JR; Florens L; Zeitlinger J; Krumlauf R
Genome Res; 2017 Sep; 27(9):1501-1512. PubMed ID: 28784834
[No Abstract] [Full Text] [Related]
5. HOXA1, a breast cancer oncogene.
Belpaire M; Taminiau A; Geerts D; Rezsohazy R
Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188747. PubMed ID: 35675857
[TBL] [Abstract][Full Text] [Related]
6. A conserved C-terminal domain in PBX increases DNA binding by the PBX homeodomain and is not a primary site of contact for the YPWM motif of HOXA1.
Green NC; Rambaldi I; Teakles J; Featherstone MS
J Biol Chem; 1998 May; 273(21):13273-9. PubMed ID: 9582372
[TBL] [Abstract][Full Text] [Related]
7. The LncRNA HOTAIRM1 Promotes Tamoxifen Resistance by Mediating HOXA1 Expression in ER+ Breast Cancer Cells.
Kim CY; Oh JH; Lee JY; Kim MH
J Cancer; 2020; 11(12):3416-3423. PubMed ID: 32284737
[TBL] [Abstract][Full Text] [Related]
8. Changing homeodomain residues 2 and 3 of Hoxa1 alters its activity in a cell-type and enhancer dependent manner.
Remacle S; Shaw-Jackson C; Matis C; Lampe X; Picard J; Rezsöhazy R
Nucleic Acids Res; 2002 Jun; 30(12):2663-8. PubMed ID: 12060683
[TBL] [Abstract][Full Text] [Related]
9. PRDM14, a putative histone methyl-transferase, interacts with and decreases the stability and activity of the HOXA1 transcription factor.
Draime A; Bridoux L; Belpaire M; Pringels T; Tys J; Rezsohazy R
Biochim Biophys Acta Gene Regul Mech; 2018 May; 1861(5):534-542. PubMed ID: 29471045
[TBL] [Abstract][Full Text] [Related]
10. NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells.
Gionet N; Jansson D; Mader S; Pratt MA
J Cell Biochem; 2009 Jun; 107(3):448-59. PubMed ID: 19350539
[TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
12. Detection of HOXA1 expression in human breast cancer.
Chariot A; Castronovo V
Biochem Biophys Res Commun; 1996 May; 222(2):292-7. PubMed ID: 8670198
[TBL] [Abstract][Full Text] [Related]
13. A six-amino-acid motif is a major determinant in functional evolution of HOX1 proteins.
Singh NP; De Kumar B; Paulson A; Parrish ME; Zhang Y; Florens L; Conaway JW; Si K; Krumlauf R
Genes Dev; 2020 Dec; 34(23-24):1680-1696. PubMed ID: 33184220
[TBL] [Abstract][Full Text] [Related]
14. Hoxa1 targets signaling pathways during neural differentiation of ES cells and mouse embryogenesis.
De Kumar B; Parker HJ; Paulson A; Parrish ME; Zeitlinger J; Krumlauf R
Dev Biol; 2017 Dec; 432(1):151-164. PubMed ID: 28982536
[TBL] [Abstract][Full Text] [Related]
15. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.
Thaler S; Schmidt M; Roβwag S; Thiede G; Schad A; Sleeman JP
Oncotarget; 2017 Sep; 8(42):72281-72301. PubMed ID: 29069787
[TBL] [Abstract][Full Text] [Related]
17. The O-GlcNAc transferase OGT interacts with and post-translationally modifies the transcription factor HOXA1.
Draime A; Bridoux L; Belpaire M; Pringels T; Degand H; Morsomme P; Rezsohazy R
FEBS Lett; 2018 Apr; 592(7):1185-1201. PubMed ID: 29465778
[TBL] [Abstract][Full Text] [Related]
18. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
19. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
20. A poly-histidine motif of HOXA1 is involved in regulatory interactions with cysteine-rich proteins.
Marchese D; Guislain F; Pringels T; Bridoux L; Rezsohazy R
Biochim Biophys Acta Gene Regul Mech; 2024 Mar; 1867(1):194993. PubMed ID: 37952572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
